Rituximab Biosimilar - Research Grade

Narsimhan et al. Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies. Analytical Chemistry, 2023, 95, 44: 16116-16122.

Human

CD20

>1mg/ml

Human IgG1 Kappa

Humanized

Bulk Anti-Human CD20 (2H7) Antibody (ICH1012), Anti-mouse CD20 (18B12) In Vivo Antibody - Low Endotoxin (ICH1277), Obinutuzumab Biosimilar - Research Grade (ICH4026), Ofatumumab Biosimilar - Research Grade (ICH4027), Veltuzumab Biosimilar - Research Grade (ICH5099), Ublituximab Biosimilar - Research Grade (ICH5297), Ibritumomab Biosimilar - Research Grade (ICH5310), Ocrelizumab Biosimilar - Research Grade (ICH5314), Blontuvetmab Biosimilar - Research Grade (ICH5409), Divozilimab Biosimilar - Research Grade (ICH5483), Epitumomab Biosimilar - Research Grade (ICH5530), Ocaratuzumab Biosimilar - Research Grade (ICH5721), Ripertamab Biosimilar - Research Grade (ICH5826), Tositumomab Biosimilar - Research Grade (ICH5937), Zuberitamab Biosimilar - Research Grade (ICH6012)

https://www.imgt.org/mAb-DB/

ICH3001-100ml ICH3002-100ml ICH3003-100ml

P11836

931

RRID:AB_2921531

Blue ice

ICH4011 is an unconjugated, non-therapeutic recombinant analog of the anti-CD20 antibody rituximab, supplied strictly for research use only. Built as a human IgG1 kappa immunoglobulin directed against the B-cell surface antigen CD20, it reproduces the binding specificity of the originator biologic without being intended for any human or veterinary clinical use. The material is well suited as a positive control and reference reagent in assays that interrogate CD20 engagement, and as a benchmarking tool when characterizing novel anti-CD20 candidates, biosimilar comparators, or Fc-engineered variants. Because it is provided in bulk milligram-to-gram quantities at research grade, with low-endotoxin (typically <1 EU/mg, or <0.5 EU/mg ultra-low) options, it is appropriate for cell-based functional work, in-vitro neutralization and cross-blocking studies, and preclinical model development where consistent lot-to-lot performance matters. Researchers commonly use it to standardize flow cytometry staining of CD20-positive B cells, to probe complement-dependent and antibody-dependent effector mechanisms, and as a scaffold reference in ADC or bispecific development pipelines. It is not the clinical drug and carries no therapeutic claim. CD20 (MS4A1) is a non-glycosylated, four-transmembrane-domain phosphoprotein of the MS4A family expressed on the surface of B lymphocytes from the late pro-B/pre-B stage through mature B cells, but absent on hematopoietic stem cells, early pro-B cells, and terminally differentiated plasma cells. It contains two extracellular loops, with the larger second loop carrying the epitope recognized by most therapeutic anti-CD20 antibodies. CD20 is not shed or internalized appreciably upon antibody binding, which contributes to its durability as a target. Functionally it is implicated in calcium influx and B-cell activation, proliferation, and differentiation, likely acting as a store-operated calcium channel component. Its restricted, lineage-specific expression makes it a foundational marker for B-cell identification and a validated target for B-cell depletion strategies.

MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7, membrane spanning 4-domains A1, FMC7

Detects human CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Rituximab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

SIM0008

Rituximab (anti-CD20) Biosimilar

Q: Is the Rituximab biosimilar available in gram quantities?

A: Yes - it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this Rituximab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Rituximab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar analog of Rituximab that binds human CD20; for research use only (RUO).